Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other research analysts also recently commented on the stock. Citizens Jmp decreased their target price on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 6th. HC Wainwright cut their price target on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, TD Cowen dropped their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.33.

Mirum Pharmaceuticals Price Performance

MIRM opened at $98.70 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The stock’s 50 day simple moving average is $110.38 and its 200 day simple moving average is $101.91. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of -6.78 and a beta of 0.52. Mirum Pharmaceuticals has a 1 year low of $58.48 and a 1 year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.12) EPS. As a group, analysts predict that Mirum Pharmaceuticals will post -4.42 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 1,840 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $105.29, for a total value of $193,733.60. Following the completion of the transaction, the senior vice president directly owned 1,274 shares in the company, valued at approximately $134,139.46. This represents a 59.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. This represents a 9.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock worth $7,185,662 over the last quarter. Corporate insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of MIRM. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $32,000. State of Wyoming purchased a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $52,000. Finally, Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.